Frontier Pharma: Neurodegenerative Diseases Protein Misfolding Targets and Neuromodulators Dominate the FirstinClass Pipeline and Lead the Way as Potential DiseaseModifying Therapies in AD and PD [Report Updated: 01112017] Prices from USD $6995
Frontier Pharma: Neurodegenerative Diseases Protein Misfolding Targets and Neuromodulators Dominate the FirstinClass Pipeline and Lead the Way as Potential DiseaseModifying Therapies in AD and PD
Summary
Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system CNS, leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring fulltime care during the later disease stages. Conditions within the therapy area are diverse, and exhibit specific pathophysiologies and etiologies, while affecting people of all ages. This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer's disease AD, Parkinson's disease PD and multiple sclerosis MS. AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into RD by pharmaceutical companies, due to high clinical trial failure rates. As a result there are no diseasemodifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Scope
Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS?
What is the current treatment algorithm?
How effective are current therapies for these indications, and how does this impact prognosis?
The AD pipeline is large and contains a very high proportion of firstinclass product innovation.
Which molecule types and molecular targets are most prominent across AD, PD and MS?
What are the connections, in terms of firstinclass innovation, between AD, PD and MS?
Which firstinclass targets are most promising?
How does the level of firstinclass innovation change within different target classes?
How do identified firstinclass molecular targets apply to AD, PD, MS and the wider therapeutic area?
How does firstinclass target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by immunomodulator products
Which indications attract the highest deal values?
How has deal activity fluctuated over the past decade?
Which firstinclass pipeline products have no prior involvement in licensing or codevelopment deals?
Reasons to buy
Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, comorbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
Identify leading products and key unmet needs within the market.
Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
Assess the therapeutic potential of firstinclass targets. Using proprietary matrix assessments, firstinclass targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising firstinclass targets are reviewed in greater detail.
Consider firstinclass pipeline products with no prior involvement in licensing and codevelopment deals, which may represent potential investment opportunities.
